These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18221196)

  • 1. Galanthamine, a natural product for the treatment of Alzheimer's disease.
    Marco L; do Carmo Carreiras M
    Recent Pat CNS Drug Discov; 2006 Jan; 1(1):105-11. PubMed ID: 18221196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of the acetylcholinesterase inhibitor galanthamine.
    Sramek JJ; Frackiewicz EJ; Cutler NR
    Expert Opin Investig Drugs; 2000 Oct; 9(10):2393-402. PubMed ID: 11060814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic and medicinal effects of snowdrop (
    Babashpour-Asl M; Kaboudi PS; Barez SR
    J Educ Health Promot; 2023; 12():128. PubMed ID: 37397105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AChE inhibitory activity of N-substituted natural galanthamine derivatives.
    Atanasova M; Stavrakov G; Philipova I; Georgiev B; Bastida J; Doytchinova I; Berkov S
    Bioorg Med Chem Lett; 2024 Nov; 112():129937. PubMed ID: 39218406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of New Galanthamine-Peptide Derivatives Designed for Prevention and Treatment of Alzheimer's Disease.
    Vezenkov LT; Tsekova DS; Kostadinova I; Mihaylova R; Vassilev NG; Danchev ND
    Curr Alzheimer Res; 2019; 16(3):183-192. PubMed ID: 30819081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alkaloid Profile in Wild Autumn-Flowering Daffodils and Their Acetylcholinesterase Inhibitory Activity.
    Lisa-Molina J; Gómez-Murillo P; Arellano-Martín I; Jiménez C; Rodríguez-Escobar ML; Tallini LR; Viladomat F; Torras-Claveria L; Bastida J
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wild Argentinian Amaryllidaceae, a new renewable source of the acetylcholinesterase inhibitor galanthamine and other alkaloids.
    Ortiz JE; Berkov S; Pigni NB; Theoduloz C; Roitman G; Tapia A; Bastida J; Feresin GE
    Molecules; 2012 Nov; 17(11):13473-82. PubMed ID: 23149565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine.
    Bores GM; Huger FP; Petko W; Mutlib AE; Camacho F; Rush DK; Selk DE; Wolf V; Kosley RW; Davis L; Vargas HM
    J Pharmacol Exp Ther; 1996 May; 277(2):728-38. PubMed ID: 8627552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alkaloids from Hippeastrum papilio.
    de Andrade JP; Berkov S; Viladomat F; Codina C; Zuanazzi JA; Bastida J
    Molecules; 2011 Aug; 16(8):7097-104. PubMed ID: 21852767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical and molecular aspects on interactions of galanthamine and its derivatives with cholinesterases.
    Gulcan HO; Orhan IE; Sener B
    Curr Pharm Biotechnol; 2015; 16(3):252-8. PubMed ID: 25483718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galanthamine.
    Fulton B; Benfield P
    Drugs Aging; 1996 Jul; 9(1):60-5; discussion 66-7. PubMed ID: 8818586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetylcholinesterase inhibitory activity of some Amaryllidaceae alkaloids and Narcissus extracts.
    López S; Bastida J; Viladomat F; Codina C
    Life Sci; 2002 Oct; 71(21):2521-9. PubMed ID: 12270757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural Alkaloids as Multi-Target Compounds towards Factors Implicated in Alzheimer's Disease.
    Vrabec R; Blunden G; Cahlíková L
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Galanthamine versus donepezil in the treatment of Alzheimer's disease].
    López-Pousa S; Garre-Olmo J; Vilalta-Franch J
    Rev Neurol; 2007 Jun 1-15; 44(11):677-84. PubMed ID: 17557224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and evaluation of galanthamine derivatives as acetylcholinesterase inhibitors.
    Jia P; Sheng R; Zhang J; Fang L; He Q; Yang B; Hu Y
    Eur J Med Chem; 2009 Feb; 44(2):772-84. PubMed ID: 18550228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of (-)- and (+)-[¹¹C]galanthamine as PET tracers for cerebral acetylcholinesterase imaging.
    Kimura H; Kawai T; Hamashima Y; Kawashima H; Miura K; Nakaya Y; Hirasawa M; Arimitsu K; Kajimoto T; Ohmomo Y; Ono M; Node M; Saji H
    Bioorg Med Chem; 2014 Jan; 22(1):285-91. PubMed ID: 24315193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
    Nordberg A; Svensson AL
    Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New classes of AChE inhibitors with additional pharmacological effects of interest for the treatment of Alzheimer's disease.
    Villarroya M; García AG; Marco JL
    Curr Pharm Des; 2004; 10(25):3177-84. PubMed ID: 15544507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent acetylcholinesterase inhibitors: design, synthesis and structure-activity relationships of alkylene linked bis-galanthamine and galanthamine-galanthaminium salts.
    Guillou C; Mary A; Renko DZ; Gras E; Thal C
    Bioorg Med Chem Lett; 2000 Apr; 10(7):637-9. PubMed ID: 10762042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.